A Study to Compare the Pharmacokinetics of BR4002 and BR4002-1 in Healthy Volunteers
NCT ID: NCT04462029
Last Updated: 2020-10-28
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
EARLY_PHASE1
18 participants
INTERVENTIONAL
2020-06-05
2020-10-07
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
CROSSOVER
TREATMENT
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
sequence 1
A total of 18 subjects will be randomized into 6 sequence groups. The investigational products (IPs) will be administered according to the treatment groups (R, T1, and T2) assigned to each sequence group in Period 1, Period 2, and Period 3. In between each period, there will be a washout period (28 days) long enough for the administered IP to be metabolized and eliminated.
* R(Reference): BR4002-1 (oral intake) 5mg single-dose
* T1(Test1): BR4002 (patch) 5mg single-dose (using the applicator)
* T2(Test2): BR4002 (patch) 5mg single-dose (not using the applicator)
sequence 1: R - T1 - T2
BR4002
* Administration to the T1 group: 5 mg of BR4002 (patch) will be attached using an applicator for 24 hours
* Administration to the T2 group: 5 mg of BR4002 (patch) will be attached without using an applicator for 24 hours
BR4002-1
Administration to the R group: 5 mg of BR4002-1 (oral formulation) will be administered with 150 mL of water
sequence 2
A total of 18 subjects will be randomized into 6 sequence groups. The investigational products (IPs) will be administered according to the treatment groups (R, T1, and T2) assigned to each sequence group in Period 1, Period 2, and Period 3. In between each period, there will be a washout period (28 days) long enough for the administered IP to be metabolized and eliminated.
* R(Reference): BR4002-1 (oral intake) 5mg single-dose
* T1(Test1): BR4002 (patch) 5mg single-dose (using the applicator)
* T2(Test2): BR4002 (patch) 5mg single-dose (not using the applicator)
sequence 2: R - T2 - T1
BR4002
* Administration to the T1 group: 5 mg of BR4002 (patch) will be attached using an applicator for 24 hours
* Administration to the T2 group: 5 mg of BR4002 (patch) will be attached without using an applicator for 24 hours
BR4002-1
Administration to the R group: 5 mg of BR4002-1 (oral formulation) will be administered with 150 mL of water
sequence 3
A total of 18 subjects will be randomized into 6 sequence groups. The investigational products (IPs) will be administered according to the treatment groups (R, T1, and T2) assigned to each sequence group in Period 1, Period 2, and Period 3. In between each period, there will be a washout period (28 days) long enough for the administered IP to be metabolized and eliminated.
* R(Reference): BR4002-1 (oral intake) 5mg single-dose
* T1(Test1): BR4002 (patch) 5mg single-dose (using the applicator)
* T2(Test2): BR4002 (patch) 5mg single-dose (not using the applicator)
sequence 3: T1 - R - T2
BR4002
* Administration to the T1 group: 5 mg of BR4002 (patch) will be attached using an applicator for 24 hours
* Administration to the T2 group: 5 mg of BR4002 (patch) will be attached without using an applicator for 24 hours
BR4002-1
Administration to the R group: 5 mg of BR4002-1 (oral formulation) will be administered with 150 mL of water
sequence 4
A total of 18 subjects will be randomized into 6 sequence groups. The investigational products (IPs) will be administered according to the treatment groups (R, T1, and T2) assigned to each sequence group in Period 1, Period 2, and Period 3. In between each period, there will be a washout period (28 days) long enough for the administered IP to be metabolized and eliminated.
* R(Reference): BR4002-1 (oral intake) 5mg single-dose
* T1(Test1): BR4002 (patch) 5mg single-dose (using the applicator)
* T2(Test2): BR4002 (patch) 5mg single-dose (not using the applicator)
sequence 4: T1 - T2 - R
BR4002
* Administration to the T1 group: 5 mg of BR4002 (patch) will be attached using an applicator for 24 hours
* Administration to the T2 group: 5 mg of BR4002 (patch) will be attached without using an applicator for 24 hours
BR4002-1
Administration to the R group: 5 mg of BR4002-1 (oral formulation) will be administered with 150 mL of water
sequence 5
A total of 18 subjects will be randomized into 6 sequence groups. The investigational products (IPs) will be administered according to the treatment groups (R, T1, and T2) assigned to each sequence group in Period 1, Period 2, and Period 3. In between each period, there will be a washout period (28 days) long enough for the administered IP to be metabolized and eliminated.
* R(Reference): BR4002-1 (oral intake) 5mg single-dose
* T1(Test1): BR4002 (patch) 5mg single-dose (using the applicator)
* T2(Test2): BR4002 (patch) 5mg single-dose (not using the applicator)
sequence 5: T2 - R - T1
BR4002
* Administration to the T1 group: 5 mg of BR4002 (patch) will be attached using an applicator for 24 hours
* Administration to the T2 group: 5 mg of BR4002 (patch) will be attached without using an applicator for 24 hours
BR4002-1
Administration to the R group: 5 mg of BR4002-1 (oral formulation) will be administered with 150 mL of water
sequence 6
A total of 18 subjects will be randomized into 6 sequence groups. The investigational products (IPs) will be administered according to the treatment groups (R, T1, and T2) assigned to each sequence group in Period 1, Period 2, and Period 3. In between each period, there will be a washout period (28 days) long enough for the administered IP to be metabolized and eliminated.
* R(Reference): BR4002-1 (oral intake) 5mg single-dose
* T1(Test1): BR4002 (patch) 5mg single-dose (using the applicator)
* T2(Test2): BR4002 (patch) 5mg single-dose (not using the applicator)
sequence 6: T2 - T1 - R
BR4002
* Administration to the T1 group: 5 mg of BR4002 (patch) will be attached using an applicator for 24 hours
* Administration to the T2 group: 5 mg of BR4002 (patch) will be attached without using an applicator for 24 hours
BR4002-1
Administration to the R group: 5 mg of BR4002-1 (oral formulation) will be administered with 150 mL of water
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
BR4002
* Administration to the T1 group: 5 mg of BR4002 (patch) will be attached using an applicator for 24 hours
* Administration to the T2 group: 5 mg of BR4002 (patch) will be attached without using an applicator for 24 hours
BR4002-1
Administration to the R group: 5 mg of BR4002-1 (oral formulation) will be administered with 150 mL of water
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
2. Body weight of ≥ 50 kg with calculated body mass index (BMI) of ≥ 18.0 to ≤ 29.0 kg/m2
3. Determined eligible based on the results of physical examination and investigator questioning conducted according to this protocol. That is, absence of congenital or chronic disease, and absence of pathological symptoms or findings based on medical examination in the last 3 years.
4. Determined eligible based on the results of the laboratory tests and electrocardiogram (ECG) conducted according to this protocol
5. Voluntarily decided to participate in the study and provided written consent to follow precautions after receiving a detailed explanation on this study and fully understanding the information
Exclusion Criteria
2. Hereditary disorders including galactose intolerance, Lapp lactase deficiency, and glucose-galactose malabsorption
3. History of heart disease such as sinus node syndrome, intra-atrial conduction disturbance or atrioventricular junctional conduction disturbance
4. Ongoing administration of non-steroidal anti-inflammatory drugs or history of peptic ulcer
5. History of asthma or obstructive pulmonary disease
6. Extrapyramidal disorder
7. Psychotic disorders or drug addiction
8. Presence or prior history of a gastrointestinal disorder or prior history of gastrointestinal surgery or skin graft that may affect the absorption of the IP
9. Presence or prior history of clinically significant cardiovascular, respiratory, hepatic, renal, neurological, endocrine, hematological and oncological, psychotic, or urinary disease
10. Clinically significant hypotension (systolic blood pressure \< 90 mmHg) or hypertension (systolic blood pressure ≥ 150 mmHg or diastolic blood pressure ≥ 95 mmHg) at screening
11. Any of the following results from screening tests:
* AST or ALT \> 2 times the upper limit of normal
* Total bilirubin \> 2.0 mg/dL
* Estimated glomerular filtration rate (eGFR) \< 60 mL/min/1.73m2
12. QTc \> 450 ms or any clinically significant abnormal finding from an ECG result at screening
13. Continuous alcohol intake or inability to stop drinking during the study period
14. Continuous smoking or inability to stop smoking throughout the hospitalization during the study period
15. Participated in another clinical study or bioequivalence study within 6 months prior to the first administration of the IP
16. Donated whole blood within 60 days or blood components within 30 days, or received blood transfusion within 30 days prior to the first administration of the IP
17. Used any prescription drugs or herbal medicines within 14 days, or any over-the-counter (OTC) drugs within 7 days prior to the first administration of the IP
18. Used drugs inducing and inhibiting drug-metabolizing enzymes, such as barbitals, within 1 month prior to initiation of the study
19. Have been on a diet (especially grapefruit juice or its product) which may affect absorption, distribution, metabolism, and excretion of the drug within 7 days prior to the first administration of the IP
20. Do not agree to exclude the possibility of pregnancy by using medically acceptable methods of contraception from the first day of administration of the IP up to 7 days after the last day of administration of the IP
21. Unwillingness or inability to comply with the diet and lifestyle guidelines required for the study
22. Clinically significant abnormal laboratory results or considered ineligible for study participation by the investigator for any other reason
23. Women who are pregnant, have a positive serum/urine hCG test, or are breastfeeding
19 Years
55 Years
ALL
Yes
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Boryung Pharmaceutical Co., Ltd
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Sang-Heon Cho
Role: PRINCIPAL_INVESTIGATOR
Inha University Hospital
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Inha University Hospital
Incheon, , South Korea
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
BR-DPZ-CT-102
Identifier Type: -
Identifier Source: org_study_id